PDZK1 acts as a tumor suppressor in gastric cancer and renal cancer, but in esophageal adenocarcinoma, breast cancer, and multiple myelomas (MMs), the overexpression of PDZK1 promotes cancer development or drug resistance (71–73). Here, PDZK1 is linked to renal carcinoma.